nanomedinc

1. Carbon Nanotube-Based Cancer Therapeutics Medical Nanotechnologies Incorporated Rob Burgess, Ph.D.Founder and President www.nanomedinc.com

2. Zyvex Corporation and Zyvex Performance Materials – Carbon Nanotube Functionalization

3. Zyvex Performance Materials’ Technical Approach Two distinct functions: • Non-damaging binding to the CNT • Customizable adhesion to host material (example: polymer such as epoxy) Zyvex NanoSolve® Enhanced Composites • Sizing agent or tailored coupling agent • Exfoliation of CNT • Uniform dispersion • Adhesion to polymer • Not a surfactant • Other advanced capabilities • Process knowledge • Custom formulations Kentera™ Technology Enables CNTs in Composites

4. Kentera-Conjugated Carbon Nanotubes are Soluble in Water • Customizable side chains confer solubility

5. RF-mediated CNT Thermal Conductivity RF field RF Transmitter RF Receiver Target area CNT-introduced regions Source: Adapted from US Patent Application 2005/0251234 A1 Inventors: Kanzius et al. Source: Gannon et al.

6. CNT Functionalization Carbon nanotubes can be functionalized with antibodies and polar lipids. AFM TEM AFM Source: Chakravarty et al. Source: Marches et al.

7. CNT Intracellular Delivery Intracellular Accumulation of PEDOT/PSS-Conjugated Carbon Nanotubes HEK293 Cells 72 hours post-treatment Source: Draper et al.

8. Carbon nanotube properties make them a unique platform for therapeutic applications. • Organized Structure • Mechanism of Action Known • RF and Near IR Sensitive • Electrically and Thermally Conductive • Can be Functionalized with a Variety of Molecules • Can Penetrate Cells

9. CNT Cytotoxicity Kentera and Kentera-conjugated carbon nanotubes are minimally cytotoxic. Source: Draper et al.

10. Antibody/CNT Cell Surface Binding and Cytotoxicity Antibody/lipid-coated carbon nanotubes are noncytotoxic and bind specifically to cancer cells. Daudi Cells Source: Chakravarty et al. Source: Marches et al.

11. Cell Surface Binding Antibody-coated carbon nanotubes bind specifically to cancer cells. Source: Chakravarty et al.

12. CNT- Based Cancer Therapeutics Cancer cells are effectively ablated by carbon nanotubes in the presence of NIR light. Source: Chakravarty et al.

13. CNT- Based Cancer Therapeutics Panc-1 cells containing Kentera-conjugated carbon nanotubes are efficiently ablated upon RF exposure. No SWNTs 11% PI Stained SWNTs 99.7% PI Stained Source: Gannon et al.

14. Intratumoral CNT/Kentera injections demonstrate RF-mediated cellular ablation. Kentera/SWNTs Kentera H&E TUNEL Source: Gannon et al.

15. Proposed Product Pipeline – Moving Towards Targeting CNTs

16. Criteria for Success: Targeted CNT Cancer Therapeutics • Functionality • Dispersion - Effective aqueous dispersion must be demonstrated. • Efficacy – CNT’s must aggressively ablate targeted tissue. • Toxicity – CNT’s and polymer functionalization must be demonstrated as nontoxic. • Specificity – CNT’s must be successfully targeted to tumorigenic tissue and away from healthy tissue.

17. Acknowledgments Zyvex Corporation Jim Von Ehr Gareth Hughes, Ph.D. Tanja Kmecko UT-Dallas Rocky Draper, Ph.D. Paul Pantano, Ph.D. Inga Musselman, Ph.D. UT-SW Medical Center Ellen Vitetta, Ph.D. Radu Marches, Ph.D. Pavitra Chakravarty, Ph.D. UT-MD Anderson Cancer Center Steve Curley, M.D. Nanoco, LLC Peter Wilk, M.D.

18. For Further Information Rob Burgess, Ph.D. President Medical Nanotechnologies, Inc. Email: rob.burgess@nanomedinc.com Phone: 214-440-2311 www.nanomedinc.com